GRI Bio, Inc. Common Stock (GRI)
GRI Bio, Inc. is a biotechnology company focused on developing therapies targeting autoimmune and inflammatory diseases. The company leverages a proprietary platform to identify and develop novel biologics aimed at modulating immune responses, with an emphasis on improving patient outcomes in conditions with unmet medical needs.
Company News
GRI Bio participated in a virtual investor segment discussing its Phase 2a study interim biomarker data for Idiopathic Pulmonary Fibrosis, highlighting potential therapeutic advances in treating inflammatory and fibrotic diseases using NKT cell modulators.
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro. Here’s the latest list of major oversold players in this sector, having an RSI near or below 30. ProSomnus, Inc. (NASDAQ: OSA) On Feb. 22, ...